Senior Scientist, Safety Assessment & Investigative Toxicology

<div class="content-intro"><p><em>Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, </em><em>is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions.</em></p> <p><em> </em><em>Headquartered in Boston, Massachusetts, Centessa was recognized as a <strong>Great Place to Work</strong>® in 2026.</em></p></div><p><strong>Description of Role</strong></p> <p>We are seeking an analytically elite, strategically minded <strong>Senior Scientist</strong> to join our Safety Assessment team. This is a <strong>100% non-laboratory position</strong> designed for a seasoned bioscientist or toxicology operations expert who thrives at the intersection of dataset auditing, mechanistic evaluation, and cross-functional project leadership.</p> <p>As a Senior Scientist, you will serve as a vital scientific and strategic hub connecting Centessa’s internal toxicology leaders with Project Development Teams (PDTs) and adjacent disciplines (including DMPK, CMC, Regulatory, and Clinical Operations). You will own the analytical pipeline for incoming toxicology studies—spearheading the audit of regulatory SEND datasets, engineering data visualizations of complex toxicology endpoints, and authoring authoritative literature reviews. Your insights will directly shape investigative toxicology strategies, driving early pipeline decision-making and securing project endorsements at internal governance committees.</p> <p><strong>Key Responsibilities</strong></p> <ul> <li><strong>Advanced Data Visualization & Analytics:</strong> Lead the architectural design and execution of data models that transform raw, multi-dose toxicology data streams, clinical pathology tables, and safety pharmacology metrics into publication-ready visual tools (e.g., exposure-margin heatmaps, benchmark dose plots, and cumulative trend diagnostics) to clearly define therapeutic windows.</li> <li><strong>SEND Strategy & Regulatory Auditing:</strong> Oversee the review and quality control of incoming Standard for the Exchange of Nonclinical Data (SEND) datasets from CRO vendors. Ensure absolute compliance, schema validation, and exact data alignment with finalized nonclinical study reports prior to regulatory filing and archival.</li> <li><strong>Mechanistic Synthesis & Literature Architecture:</strong> Conduct rigorous, comprehensive scientific literature investigations to proactively assess target-mediated or chemotype-specific safety risks. Synthesize complex, ambiguous biological data into clear, actionable technical memos that inform investigative toxicity strategies.</li> <li><strong>PDT & Governance Leadership:</strong> Partner closely with Toxicology Leads to co-author high-impact data packages, briefing books, and executive slide decks. Actively participate in defending safety strategies and securing program endorsements within Project Development Teams (PDTs) and formal internal governance panels.</li> <li><strong>Cross-Functional Synergy:</strong> Act as a senior scientific liaison between Safety Assessment, CMC (for compound inventory tracking), DMPK (for toxicokinetic integration), and Project Management to ensure nonclinical safety deliverables